Decreased Plasma IL-35 Levels Are Related to the Left Ventricular Ejection Fraction in Coronary Artery Diseases


Advertisements
Advertisements

ABSTRACT: Decreased Plasma IL-35 Levels Are Related to the Left Ventricular Ejection Fraction in Coronary Artery Diseases

Background

Accumulating evidence shows that the novel anti-inflammatory cytokine IL-35 can efficiently suppress effector T cell activity and alter the progression of inflammatory and autoimmune diseases. The two subunits of IL-35, EBI3 and p35, are strongly expressed in human advanced plaque, suggesting a potential role of IL-35 in atherosclerosis and coronary artery disease (CAD). However, the plasma levels of IL-35 in patients with CAD have yet to be investigated.

Methods

Plasma IL-35, IL-10, TGF-β1, IL-12 and IL-27 levels were measured using an ELISA in 43 stable angina pectoris (SAP) patients, 62 unstable angina pectoris (UAP) patients, 56 acute myocardial infarction (AMI) patients and 47 chest pain syndrome patients as a control group.

Results

The results showed that plasma IL-35 levels were significantly decreased in the SAP group (90.74±34.22 pg/ml), the UAP group (72.20±26.63 pg/ml), and the AMI group (50.21±24.69 pg/ml) compared with chest pain syndrome group (115.06±32.27 pg/ml). Similar results were also demonstrated with IL-10 and TGF-β1. Plasma IL-12 and IL-27 levels were significantly increased in the UAP group (349.72±85.22 pg/ml, 101.75±51.42 pg/ml, respectively) and the AMI group (318.05±86.82 pg/ml, 148.88±68.45 pg/ml, respectively) compared with chest pain syndrome group (138.68±34.37 pg/ml, 63.60±22.75 pg/ml, respectively) and the SAP group (153.84±53.86 pg/ml, 70.84±38.77 pg/ml, respectively). Furthermore, lower IL-35 levels were moderately positively correlated with left ventricular ejection fraction (LVEF) in CAD patients (R = 0.416, P<0.01), whereas higher IL-27 levels were weakly negatively correlated with LVEF in CAD patients(R = −0.205, P<0.01).

Conclusions

The results of the present study show that circulating IL-35 is a potentially novel biomarker for coronary artery disease. Regulating the expression of IL-35 also provides a new possible target for the treatment of atherosclerosis and CAD.

____________________________

Publisher: Public Library of Science

Date Published: 21-December-2012

Author(s): Lin Y., Huang Y., Lu Z., Luo C., shi Y., Zeng Q., Cao Y., Liu L., Wang X., Ji Q.

Link: https://doi.org/10.1371/journal.pone.0052490


Related Links:

Scientific Facts About Vitamin D – Chromoscience. Vitamin D treatment can improve the ejection fraction of the heart. Vitamin D supplementation does not improve liver enzymes, insulin resistance, …

Research Highlights: Macrophages Pick-up “Trash” from Heart … The ejection process is driven by the cardiomyocyte’s autophagy machinery that … pathogenesis of heart failure with preserved ejection fraction (HFpEF).

Research Summary: Evolution of anti-Trypanosoma cruzi antibody … Strong inverse correlation (ρ = -0.6375, p = 0.0005) between anti- T . cruzi IgG1 titers and left ventricular ejection fraction (LVEF) in chronic Chagas …

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Butler J, Packer M, Filippatos G, Ferreira JP, Zeller C, Schnee J, Brueckmann M, Pocock SJ, Zannad F, Anker SD.

Left Ventricular Ejection Fraction. Kosaraju A, Goyal A, Grigorova Y, Makaryus AN.

Managing heart failure with preserved ejection fraction. Davidson A, Raviendran N, Murali CN, Myint PK.

Leave a Reply

Your email address will not be published. Required fields are marked *